登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 特别提示： 2024年度股东大会、2025年第一次A股类别股东会及2025年第一次H股类别股东会没有出现否决议案的 情形，未涉及变更以往股东大会已通过的决议。 一、会议的召集、召开和出席情况 1、股东大会届次：丽珠医药集团股份有限公司（以下简称"公司"）2024年度股东大会、2025年第一次 A股类别股东会及2025年第一次H股类别股东会。 2、股东大会的召集人：公司董事会。公司已于2025年4月23日召开了第十一届董事会第二十四次会议， 审议通过了《关于召开公司2024年度股东大会、2025年第一次A股类别股东会及2025年第一次H股类别 股东会的议案》。 3、股东大会的主持人：副董事长陶德胜先生。 ③2025年第一次H股类别股东会召开日期、时间：2025年5月29日（星期四）下午3:30（或紧随公司2025 年第一次A股类别股东会结束后）。 （2）网络投票时间： ①通过互联网投票系统进行网络投票的起止日期和时间：2025年5月29日上午9:15至2025年5月 ...

特此公告。 丽珠医药集团股份有限公司董事会 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：000513、01513 证券简称：丽珠集团、丽珠医药 公告编号：2025-039 丽珠医药集团股份有限公司 关于2022年股票期权激励计划部分股票期权注销完成的公告 本公司及董事会全体成员保证信息披露内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 丽珠医药集团股份有限公司（以下简称"公司"）于2025年4月23日召开了第十一届董事会第二十四次会 议，审议通过了《关于注销2022年股票期权激励计划部分股票期权的议案》，同意对公司2022年股票期 权激励计划首次授予第一个行权期内31名激励对象到期尚未行权的38.4045万份股票期权予以注销；因 公司首次授予股票期权第三个行权期及预留授予股票期权第二个行权期对应公司层面业绩考核目标不达 标，同意对2022年股票期权激励计划首次授予股票期权第三个行权期对应的528.3750万份和预留授予股 票期权第二个行权期对应的100.00万份股票期权进行注销。有关详情请见公司于2025年4月24日在《中 国证券报》《证券时报》《证券日报》《上海证券报》及巨潮资 ...

Revenue and Profit - Revenue for Q1 2025 was CNY 3,180,547,599.31, a decrease of 1.92% compared to CNY 3,242,814,513.73 in the same period last year[7] - Net profit attributable to shareholders increased by 4.75% to CNY 636,707,931.59 from CNY 607,823,809.46 year-on-year[7] - Basic earnings per share rose by 9.23% to CNY 0.71 from CNY 0.65 in the previous year[7] - The total operating revenue for the current period is RMB 3,180,547,599.31, a decrease of 1.92% from RMB 3,242,814,513.73 in the previous period[30] - The net profit for the current period is RMB 803,641,985.42, representing an increase of 12.24% compared to RMB 716,078,960.15 in the previous period[30] - The operating profit for the current period is RMB 958,924,963.25, up from RMB 848,887,058.48 in the previous period, indicating a growth of 12.93%[30] Cash Flow and Investments - The net cash flow from operating activities decreased by 21.59% to CNY 724,730,912.38 compared to CNY 924,248,920.31 in the same period last year[7] - Investment cash inflow increased significantly to RMB 32,290,697.41, a 434.99% increase compared to the previous year[17] - Investment cash outflow decreased to RMB 254,040,597.78, a reduction of 45.18% year-on-year[17] - Net cash generated from investment activities improved to -RMB 221,749,900.37, a 51.51% reduction in losses compared to the previous year[17] - The net increase in cash and cash equivalents was RMB 3,627,344.76, a 101.93% improvement from a net decrease of RMB 188,391,565.87 in the previous year[17] - The cash flow from foreign currency exchange losses increased significantly to -RMB 11,438,352.18, a 1,557.26% decline compared to the previous year[17] - The company has reduced bank loan repayments, contributing to the improved cash flow situation[17] - The net cash flow from investing activities was negative at RMB -221,749,900.37, an improvement from RMB -457,336,601.18 in the previous period[32] - The net cash flow from financing activities was negative at RMB -487,915,315.07, compared to RMB -654,613,688.15 previously, showing a reduction in cash outflow[33] Assets and Liabilities - Total assets at the end of the reporting period were CNY 24,485,271,838.40, reflecting a slight increase of 0.12% from CNY 24,455,825,697.18 at the end of the previous year[8] - The total liabilities decreased to RMB 9,109,970,328.17 from RMB 9,550,079,103.14, a reduction of approximately 4.62%[29] - The cash and cash equivalents at the end of the period are RMB 10,830,774,329.69, showing a marginal increase from RMB 10,827,146,984.92 at the beginning of the year[27] - The inventory at the end of the period is RMB 1,900,256,033.70, a decrease of 4.87% from RMB 1,997,642,296.29 at the beginning of the year[27] Shareholder Information - The total number of common shareholders at the end of the reporting period was 52,367, with 52,348 being A-share shareholders[19] - The largest shareholder, Hong Kong Central Clearing Limited, holds 33.66% of shares, totaling 306,769,189 shares[20] - The company repurchased a total of 9,425,955 A-shares, accounting for 1.03% of the total share capital, with a total expenditure of RMB 341,957,191.15[24] - The company also repurchased 7,245,300 H-shares, representing 0.80% of the total share capital, with a total expenditure of HKD 190,692,395.00[25] Other Financial Metrics - Other income increased by 55.27% to CNY 44,485,866.21, primarily due to an increase in government subsidies received[16] - The company reported a significant decrease of 84.84% in trading financial liabilities, down to CNY 1,227,675.21 from CNY 8,096,946.08, mainly due to changes in forward foreign exchange contracts[15] - The company’s inventory write-down provision increased, leading to a 55.10% rise in asset impairment losses to CNY -6,355,971.69 from CNY -4,097,945.69 in the previous year[16] - The company's retained earnings increased to RMB 12,398,087,110.19 from RMB 11,761,379,178.60, reflecting a growth of 5.43%[29] - The total comprehensive income for the period was RMB 790,563,380.41, an increase from RMB 693,127,170.79 in the previous period, representing a growth of approximately 14%[31] - The other comprehensive income attributable to the parent company's shareholders was RMB -12,213,875.83, an improvement from RMB -23,160,894.39 in the previous period[31] - The cash inflow from financing activities totaled RMB 630,140,000.00, down from RMB 721,939,862.90, indicating a decrease of approximately 12.7%[33] - The company reported a decrease in cash outflows for operating activities, totaling RMB 2,703,265,415.19, compared to RMB 2,584,514,895.68, reflecting an increase of about 4.6%[32] - Research and development expenses for the current period are RMB 216,076,782.61, down from RMB 238,173,559.46 in the previous period, a decrease of 9.25%[30]

Financial Performance - In 2024, Livzon Pharmaceutical Group achieved a revenue of RMB 11,812.34 million and a net profit attributable to shareholders of RMB 2,061.10 million[10]. - The company achieved a total revenue of RMB 12,430.04 million, with a year-on-year decrease of 4.97%[21]. - The net profit attributable to shareholders was RMB 1,953.65 million, reflecting a decline of 8.31% compared to the previous year[21]. - The company reported a net cash flow from operating activities of RMB 2,061.10 million, showing a significant increase of 51.80%[21]. - The company’s basic earnings per share for the year was RMB 2.10, with a diluted earnings per share of RMB 2.24[21]. - The company reported a total operating revenue for the year 2024 of RMB 11,812,338,854.68, representing a decrease of 4.97% compared to RMB 12,430,038,325.82 in 2023[106]. - The net profit attributable to shareholders increased by 5.50% to RMB 2,061,095.80 million in 2024[54]. - The company reported a gross margin of 45%, maintaining a stable margin compared to the previous year[37]. Research and Development - Research and development (R&D) investment accounted for 8.84% of total revenue, focusing on gastrointestinal, reproductive assistance, and mental health fields[14]. - The company has 45 products in the pipeline, including 23 innovative drugs and high-barrier complex formulations[14]. - Livzon has introduced six new projects through business development collaborations, enhancing its R&D pipeline[16]. - AI technology has been integrated into the entire R&D process, significantly improving efficiency[16]. - The company plans to increase investment in innovative drug research and development, focusing on core therapeutic areas such as digestive, mental health, and reproductive health[19]. - The company is focusing on self-research and business development (BD) to drive innovation, with a particular emphasis on gastrointestinal, reproductive, and neurological fields[73]. - The company has multiple products in various stages of clinical trials, including 3 in Phase III and 2 in Phase I[80]. - The company has established a modular and flat R&D management system to improve efficiency in project management and resource allocation[73]. Market Expansion - The company is expanding its market presence from emerging markets to Europe and the United States, optimizing its product offerings[17]. - Livzon is expanding its market presence in Southeast Asia, aiming to increase sales by 25% in that region[37]. - The company is actively pursuing international partnerships to introduce advanced technologies and expand its competitive products into global markets[93]. - The company has established branches in Malaysia and offices in Brazil, India, Spain, Vietnam, and Turkey to enhance its global commercialization strategy[101]. Product Development - Livzon plans to launch three new products in the next fiscal year, focusing on innovative drug development and biotechnology[37]. - The company has initiated Phase III clinical trials for a recombinant anti-IL-17A/F monoclonal antibody for psoriasis, aiming for market approval by 2025[76]. - The company has received approvals for three products during the reporting period, including potassium bismuth citrate granules and hydrochloride pramipexole tablets (8mg)[81]. - The company is focusing on high clinical value products, with a complete matrix of assisted reproductive products expected to enhance market presence[79]. - The company is advancing its research in traditional Chinese medicine, targeting mental health and chronic diseases, with two products expected to report this year[79]. Compliance and Sustainability - The company maintains a 100% compliance rate with GMP inspections for all production lines of listed products[18]. - The company has received MSCI ESG AAA rating for two consecutive years and was recognized as the "Best Progress Company" in the 2024 S&P Global Sustainability Yearbook[19]. - The company integrates sustainable development goals into management performance assessments, promoting green production and social responsibility[94]. - The company has established a standardized public welfare management system focusing on rural revitalization, education support, medical assistance, and disaster response, contributing to local farmers' income through the "Huangqi Industry Revitalization" project[95]. Financial Management - The company reported a total investment amount of RMB 1,711,305,473.04, representing a 134.54% increase compared to RMB 729,635,150.00 in the previous year[161]. - The company has established risk management measures for foreign exchange and commodity futures derivatives to mitigate market risks associated with currency and commodity price fluctuations[171]. - The company has not engaged in speculative derivative investments during the reporting period[172]. - The company has implemented strict internal controls to reduce operational risks related to derivative trading[171]. Customer and Supplier Relations - The average duration of the top five customers' relationship with the company is 16.60 years, indicating strong customer loyalty[114]. - The company’s total revenue from the top five customers was RMB 947,987,674.38, representing 8.10% of the total annual sales, slightly down from 8.19% in 2023[115]. - The total procurement amount from the top five suppliers was RMB 706,067,451.82, which accounted for 32.15% of the total procurement, an increase from 26.06% in 2023[119].

3月31日，丽珠集团（000513）发布了向控股子公司珠海市丽珠生物医药科技有限公司（以下简称丽珠 生物）增资的更新公告，拟以10亿元认购丽珠生物新增注册资本，以认购丽珠生物此次增资后18.85% 的出资比例的认购价。 作为丽珠集团的抗体药物、重组蛋白药物以及重组蛋白疫苗等创新生物药研发的唯一平台，丽珠生物目 前仍处于亏损之中。 丽珠生物仍处亏损中 根据丽珠集团与丽珠生物签订的增资协议约定，丽珠集团拟出资10亿元认购丽珠生物新增的注册资本 2.06亿元，以认购丽珠生物增资后18.85%的出资比例的认购价。丽珠生物注册资本将从10.95亿元增加 至13.02亿元，其中新增的注册资本全部由丽珠集团认缴，认缴款总额为10亿元，其中2.06亿元计入丽珠 生物注册资本，7.94亿元计入资本公积。本次增资完成后，丽珠集团持有的丽珠生物股份（600201）增 加至66.54%。 此次增资主要基于双方在2023年11月签订的协议，即丽珠生物注册资本由原来的8.89亿元增加至10.95亿 元，由丽珠集团以货币出资方式于2028年12月31日前缴清认缴本次新增的注册资本2.06亿元，认购对价 为10亿元，超过认缴出资额部分的认购 ...

一、原披露内容："根据《增资协议》约定，公司同意出资人民币100,000.00万元认购丽珠生物新发行的 206,449,050股普通股。" 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：000513、01513 证券简称：丽珠集团、丽珠医药 公告编号：2025-027 丽珠医药集团股份有限公司 更正公告 本公司及董事会全体成员保证信息披露内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 丽珠医药集团股份有限公司（以下简称"公司"）于2025年3月27日在指定信息披露媒体《中国证券报》 《证券时报》《证券日报》《上海证券报》及巨潮资讯网（www.cninfo.com.cn）上发布了《丽珠医药 集团股份有限公司关于向控股子公司丽珠生物增资暨关联交易的公告》（公告编号：2025-023）。因公 告内容有误，现更正如下： 现更正为："根据《增资协议》约定，公司同意出资人民币100,000.00万元认购丽珠生物新增的注册资本 人民币206,449,050元。" 二、原披露内容："本次交易金额是经交易双方公平磋商，为了满足丽珠生物的资金需求，并参考2023 年11月17日公司与丽珠生物签署的《关 ...

Financial Performance - The company achieved a revenue of RMB 11,812.34 million for the fiscal year ending December 31, 2024, with a net profit attributable to shareholders of RMB 2,061.10 million[12]. - The total revenue for the year was RMB 12.430 billion, with a net profit attributable to shareholders of RMB 2.061 billion[23]. - The company's operating revenue for 2024 was RMB 11,812,338.85 million, a decrease of 4.97% compared to 2023[56]. - Net profit attributable to shareholders increased by 5.50% to RMB 2,061,095.80 million in 2024[56]. - The basic earnings per share rose by 6.67% to RMB 2.24 in 2024[56]. - The net cash flow from operating activities decreased by 8.31% to RMB 2,978,847.53 million[56]. - Total assets decreased by 2.35% to RMB 24,455,825.70 million as of December 31, 2024[56]. - Total liabilities decreased by 7.08% to RMB 9,550,079.10 million[56]. - The return on equity for shareholders increased to 14.87%, up by 0.96 percentage points from 2023[56]. - The company reported a total of RMB 81,899,978.50 million in non-recurring gains and losses for 2024[60]. Research and Development - R&D investment accounted for 8.84% of total revenue, focusing on gastrointestinal, reproductive assistance, and mental health fields[16]. - The company has 45 products in the pipeline, including 23 innovative drugs and high-barrier complex formulations[16]. - AI technology has been integrated into the entire R&D process, enhancing efficiency in drug discovery and clinical research[18]. - The company plans to increase investment in innovative drug research and development, focusing on core therapeutic areas such as digestive, mental health, and reproductive assistance[21]. - The company reported a total R&D expenditure of approximately RMB 1.044 billion, accounting for about 8.84% of total revenue[75]. - The company is focusing on self-research and business development (BD) to drive innovation, particularly in gastrointestinal, reproductive, and neurological fields[75]. - The company has established a modular and flat R&D management system to improve efficiency in project management and resource allocation[75]. - The company has initiated Phase III clinical trials for a recombinant anti-IL-17A/F monoclonal antibody for psoriasis, aiming for market submission in 2025[78]. - The company is advancing multiple high-barrier complex formulations and high clinical value products, with several expected to be submitted for listing by 2025[82]. Market Expansion and Sales - The company reported a 65.98% year-on-year increase in overseas sales revenue for its formulation products[17]. - The export revenue of raw materials and intermediates reached RMB 1.668 billion, an increase of 7.93% year-on-year[19]. - The company achieved overseas revenue of RMB 1.724 billion, accounting for 14.59% of total revenue, with a year-on-year growth of 9.69%[92]. - The overseas sales revenue of formulation products grew by 65.98%, covering areas such as reproductive assistance and antiviral products[94]. - The company completed 202 international registration projects for APIs and intermediates in 94 countries/regions, obtaining 32 international certification certificates[93]. - The company has established branches in Malaysia and offices in Brazil, India, Spain, Vietnam, and Turkey to enhance its global commercialization strategy[103]. Compliance and Quality Management - The group achieved 100% compliance with GMP inspections for all production lines of listed products, with zero 483 records during FDA inspections[20]. - The company emphasizes compliance with the Chinese Accounting Standards and relevant regulations[35]. - The company has implemented strict compliance measures in its marketing activities, establishing a comprehensive risk monitoring mechanism[87]. - The company has established a comprehensive quality management system covering the entire product lifecycle, ensuring continuous improvement in production operations[89]. Corporate Governance and Sustainability - The company has been rated MSCI ESG AAA for two consecutive years and was recognized as the "Best Progress Company in the Industry" in the 2024 Sustainable Development Yearbook[21]. - The company integrates sustainable development goals into management performance assessments, promoting green production and social responsibility[96]. - The company has established a standardized public welfare management system focusing on rural revitalization, education support, medical assistance, and disaster response, contributing to local farmers' income through the "Huangqi Industry Revitalization" project[97]. Investment and Financial Strategy - The company approved a credit limit of RMB 26,455.00 million, with actual bank credit utilized amounting to RMB 4,678.36 million[148]. - The company has committed a total investment of RMB 142,030.04 million for various projects, with a cumulative investment of RMB 142,030.04 million achieved by the end of the reporting period[181]. - The company plans to use the raised funds for the deep development and industrialization of the Aiprazole series innovative products, construction of a long-acting microsphere technology R&D platform, and expansion projects[178]. - The company has established a foreign exchange risk management policy to hedge against currency fluctuations affecting its foreign currency assets[173]. - The company has implemented strict controls to prevent speculative trading in its derivative investments, adhering to a prudent and stable operational principle[173]. Employee and Organizational Development - The company has a research and development team of over 900 members, ensuring efficient project execution and rapid transformation of introduced research projects[100]. - The company has developed a digital training platform, "Lizhu Cloud Academy," providing over 100 hours of training per employee annually to support career development[98]. - The number of R&D personnel increased slightly by 0.22% to 908, with a notable increase in bachelor's degree holders by 7.13% to 556[130].

自12月4日以来公司已连续15日进行回购，合计回购298.83万股，累计回购金额8096.97万港元。 其间该 股累计上涨1.31%。 丽珠医药回购明细 证券时报•数据宝统计，丽珠医药在港交所公告显示，12月24日以每股26.850港元至27.200港元的价格回 购15.27万股，回购金额达413.97万港元。该股当日收盘价27.100港元，上涨0.93%，全天成交额1029.16 万港元。 今年以来该股累计进行86次回购，合计回购2589.78万股，累计回购金额8.42亿港元。（数据宝） ...

Financial Performance - Operating revenue for Q3 2024 was RMB 2,799,249,537.14, down 5.59% year-over-year, while year-to-date revenue was RMB 9,081,603,788.36, a decrease of 5.94%[2] - Net profit attributable to shareholders for Q3 2024 was RMB 501,763,106.12, an increase of 7.45% year-over-year, with year-to-date net profit at RMB 1,672,733,989.63, up 4.44%[2] - Basic earnings per share for Q3 2024 was RMB 0.54, reflecting an increase of 8.00% compared to the same period last year[2] - The company's operating revenue for the first nine months of 2024 was RMB 9,081.60 million, a decrease of 5.94% compared to RMB 9,654.79 million in the same period of 2023[6] - Operating profit increased to RMB 2,315,421,100.65, up 16.48% from RMB 1,987,239,809.53 year-on-year[17] - Net profit attributable to shareholders of the parent company reached RMB 1,672,733,989.63, representing a growth of 4.44% compared to RMB 1,601,554,878.96 in the previous year[17] - Total comprehensive income for the first nine months of 2024 was RMB 1,896,000,641.95, an increase from RMB 1,548,036,443.08 year-on-year[18] Assets and Liabilities - Total assets at the end of the reporting period amounted to RMB 24,909,308,152.30, a decrease of 0.54% compared to the previous year-end[2] - The total current assets decreased from RMB 17,266,174,718.28 at the beginning of the year to RMB 16,613,394,001.59 at the end of the period[15] - The company's cash and cash equivalents decreased from RMB 11,325,723,855.76 to RMB 10,732,685,456.90[15] - The total non-current assets increased from RMB 7,778,652,409.47 to RMB 8,295,914,150.71[15] - Total liabilities decreased to RMB 9,973,518,408.08 from RMB 10,278,124,131.71, a reduction of 2.97%[16] - Current liabilities increased to RMB 9,013,265,318.62, up 11.43% from RMB 8,087,137,474.74 at the beginning of the year[16] - The company's total equity attributable to shareholders of the parent company rose to RMB 14,158,595,462.73, an increase from RMB 14,042,495,302.72[16] Cash Flow - The net cash flow from operating activities for the year-to-date period was RMB 2,307,915,362.28, reflecting a growth of 4.32%[2] - Operating cash inflow for the period (January to September 2024) was RMB 10,217,108,238.70, a decrease of 5.2% from RMB 10,775,261,897.57 in the same period of 2023[19] - Net cash flow from operating activities increased to RMB 2,307,915,362.28, up 4.3% from RMB 2,212,403,355.39 year-on-year[19] - Cash inflow from financing activities increased to RMB 3,166,957,767.39, up 14.3% from RMB 2,770,410,168.70 in the previous year[20] - Net cash flow from financing activities was negative at RMB -1,912,251,596.10, worsening from RMB -1,768,301,850.08 year-on-year[20] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 41,320, with the top ten shareholders holding significant stakes[8] - The largest shareholder, Hong Kong Central Clearing Limited, held 33.11% of the shares, amounting to 306,768,789 shares[8] - As of September 30, 2024, the company repurchased a total of 7,855,000 A-shares, accounting for 0.85% of the total share capital, with a total expenditure of RMB 276,508,263.84[12] - The company repurchased 4,763,400 H-shares, with 2,778,800 shares canceled on June 28, 2024, representing 0.21% of the total share capital, and a total expenditure of HKD 116,981,345.00[13] Other Financial Metrics - Financial expenses decreased by 74.63% to RMB -54.93 million, primarily due to reduced interest income and foreign exchange fluctuations[6] - Investment income fell by 48.98% to RMB 25.90 million, mainly due to changes in the profits of associated companies[6] - Research and development expenses were RMB 734,493,897.75, down 25.49% from RMB 985,755,413.94 in the same period last year[17] - Other comprehensive income after tax showed an improvement, with a net amount of RMB -49,894,257.61 compared to RMB -76,284,738.91 in the previous year[18] - The fair value change income was RMB -5.50 million, an improvement of 86.90% compared to RMB -41.99 million in the previous year, mainly due to fluctuations in the market value of securities investments[6]

Financial Performance - The total revenue for the first half of 2024 was RMB 6,282.35 million, representing a decrease of 6.09% compared to the same period in 2023[17]. - The net profit attributable to shareholders was RMB 1,170.97 million, down 3.21% year-over-year[17]. - The cash flow from operating activities was RMB 1,155.47 million, reflecting a decrease of 5.65% compared to the previous year[17]. - The basic earnings per share increased to RMB 1.27, up 4.10% from RMB 1.22 in the same period last year[18]. - The overall revenue from raw materials and intermediates was RMB 745.01 million, reflecting a decrease of 11.86%[20]. - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB for the first half of 2024, representing a 15% year-over-year growth[33]. - The company reported a revenue of RMB 6,282.35 million for the first half of 2024, a decrease of 6.09% compared to RMB 6,689.92 million in the same period last year[46]. - Net profit attributable to shareholders was RMB 1,170.97 million, reflecting a growth of 3.21% from RMB 1,134.57 million year-on-year[46]. - The net profit excluding non-recurring gains and losses was RMB 1,155.47 million, an increase of 5.65% from RMB 1,093.71 million in the previous year[47]. - The net cash flow from operating activities increased by 24.67% to RMB 1,530.03 million, compared to RMB 1,227.31 million in the previous period[40]. Revenue Breakdown - The revenue from chemical preparations accounted for 28.03% of total revenue, amounting to RMB 1,761.08 million[20]. - The revenue from biological products decreased by 61.23%, totaling RMB 70.52 million[21]. - The company’s revenue from traditional Chinese medicine preparations increased by 32.33%, reaching RMB 394.35 million[21]. - Sales revenue from chemical preparations was RMB 3,223.84 million, a decline of 7.37%, accounting for 51.32% of the total revenue[49]. - The sales revenue of the biopharmaceutical segment was RMB 87.55 million, a year-on-year decrease of 22.80%, accounting for 1.39% of the total revenue[55]. - The sales revenue of raw materials and intermediates segment reached RMB 1,761.08 million, a year-on-year decrease of 1.16%, accounting for 28.03% of the total revenue[58]. - The sales revenue of traditional Chinese medicine preparations was RMB 745.01 million, down 21.89% year-on-year, representing 11.86% of total revenue[62]. - The sales revenue of diagnostic reagents and equipment increased by 32.33% year-on-year to RMB 394.35 million, making up 6.28% of total revenue[64]. Future Outlook and Strategies - The company has provided a positive outlook for the second half of 2024, projecting a revenue growth of 10% to 12%[33]. - New product development includes the launch of a novel drug expected to enter the market by Q4 2024, which is anticipated to generate an additional 300 million RMB in revenue[33]. - The company is expanding its market presence in Southeast Asia, targeting a 25% market share in the region by 2025[33]. - A strategic acquisition of a local pharmaceutical company is in progress, which is expected to enhance the company's production capacity by 30%[33]. - The company plans to enhance its digital marketing strategies, aiming for a 15% increase in online sales by the end of 2024[33]. - The company is focusing on core areas such as gastrointestinal, neuropsychiatric, reproductive assistance, metabolism, and anti-infection for its chemical preparations segment in the second half of 2024[53]. Research and Development - The company has invested 100 million RMB in R&D for innovative drug formulations in the first half of 2024, a 50% increase from the previous year[33]. - The company has made significant progress in key projects, including the approval of the 8 mg hydrochloride paliperidone tablets and the submission of supplementary materials for the injection of triptorelin microspheres for endometriosis[50]. - The company is advancing the development of key biopharmaceutical projects, including the completion of patient enrollment for the phase III clinical trial of recombinant human follicle-stimulating hormone injection[55]. - The company is actively expanding its international business, with the injection of acetic acid cyproterone approved for sale in the United States and ongoing sales and registration efforts in multiple countries[51]. - The company has established a modular and flat R&D management system, enhancing project management and resource allocation for competitive innovation projects[50]. - The company is focusing on evidence-based marketing and compliance marketing to promote its core products effectively[51]. Investment and Financial Management - The company has received emergency use approval for its bivalent COVID-19 vaccine, which has been shipped to multiple provinces for vaccination[56]. - The company aims to accelerate the commercialization process of its biopharmaceutical products while enhancing its quality management system[57]. - The company has a rolling bill pool business limit of RMB 1.8 billion, with a pledged balance of RMB 296,090,600[104]. - The company has received production approval for several new products, including the injection of aripiprazole microspheres for schizophrenia, which is expected to enhance its product offerings[81]. - The company has made significant equity investment of RMB 1,000,000,000 in Zhuhai Lizhu Biological, holding a 60.23% stake[133]. - The company reported a loss from the investment in Zhuhai Lizhu Biological of RMB -106,335,367.68[134]. - The company has established a management system for commodity futures hedging to mitigate market risks associated with commodity price fluctuations[142]. Share Repurchase and Capital Management - The company approved a share repurchase plan for A-shares with a total fund amount between RMB 400 million and RMB 600 million, with a maximum repurchase price of RMB 38.00 per A-share[199]. - As of June 30, 2024, the company repurchased a total of 2,152,600 A-shares, accounting for 0.23% of the total issued share capital and 0.35% of the total issued A-shares, with a total expenditure of RMB 73,436,534.00[199]. - In July 2024, the company repurchased an additional 2,741,600 A-shares, representing 0.30% of the total issued share capital and 0.44% of the total issued A-shares, with a total expenditure of RMB 98,431,542.00[200]. - The repurchased A-shares have not yet been canceled and will reduce the registered capital upon cancellation[200]. - The company aims to stabilize its development and protect shareholder interests through this repurchase initiative[199].